PCRI is proud to welcome John Anderson to our Board of Directors. His experience will be invaluable to our leadership team as he helps to advance our mission.

AUA is an annual meeting of urologists where data from new studies are presented. This data is presented in abstracts, or summaries of the entire peer reviewed articles. In this article, Mark Scholz, MD, analyzes the data and explains the practical implications of these new studies.

Dr. Moyad is challenging you to step outside your comfort zone and reach a new level of physical and mental health. To take the challenge, visit www.pcri.org to see a list of suggested activities, or create your own. When you complete your chosen activity, you will upload a picture and a quick paragraph about what you learned from your experience.

Radium-223 is used to treat bone metastases, a common problem for men living with metastatic hormone resistant prostate cancer (MHRPC), affecting up to 90% of these patients. The development of a drug called radium-223 (brand name: Xofigo) is a substantial innovation, not only because it causes less toxicity compared to its predecessors, but also because it prolongs life.

Greetings researcher, and welcome to a new edition of Prostate Insights. We have exciting things to announce and important information about new and current treatments. More treatments are becoming available today for men who have metastatic prostate cancer. More treatments are becoming available today for men who have metastatic prostate cancer. William K. Oh, MD and Charlie Baker from the Tisch Cancer Institute will provide an overview of the unique radiotherapy called Xofigo (radium-223)...

Many of you may have noticed that the Prostate Snatcher’s Blog has been temporarily on hold.  Ralph Blum, my coauthor of the Blog, passed away in March at the age of 84.  Ralph underwent surgery for a non-prostate-cancer-related abdominal problem and unfortunately was never able to recover.
This has been a sad time for me.  In fact, I needed the last couple months to get my emotions settled down before restarting the Blog. Winston Churchill said, "We make a living by what we get, but we make a life by what we give." Ralph, thank you for everything you gave us.

If you have been diagnosed with prostate cancer and are unable to work, you may be worried about making ends meet. Fortunately, the Social Security Administration (SSA) provides financial benefits for people who are unable to work due to an illness.

Metastatic, late stage, and terminal prostate cancers automatically meet the SSA’s medical eligibility requirements for disability benefits. Prostate cancer that is diagnosed early and response to treatment, however, may or may not qualify you for benefits.

In this blog PCRI presents an interview from our contributing partner, Prostatepedia. 

Prostatepedia spoke at length with Dr. Laurence Klotz about why testosterone levels are significant in prostate cancer. Dr. Laurence Klotz is an esteemed Urological Oncologist from the University of Toronto. He is one of the driving forces behind the development of active surveillance as a viable approach for men with slow-growing, non-aggressive prostate cancer. Here is the interview:

Sunnybrook Health Sciences Centre’s Laurence Klotz, MD, speaks with PCRI about management of low-risk prostate cancer with Active Surveillance. 

What is active surveillance, and how does it compare with other methods of treating prostate cancer?

The concept of conservative management for prostate cancer is not new. In fact, in Scandinavia and England in the 70s, basically no one was treated until they had metastatic disease. And the idea was that treatment....

We're pleased to announce that we'll be working with KMI on videos for the new SHADES program. Stay tuned for more information on this groundbreaking patient education series.

In the mean, time check out our Prostate Cancer 101 video series below: